SCHEMBL22201058

SCHEMBL22201058

Cc1cc(N2CCN(C(=O)OC(C)(C)C)C[C@@H]2C)cc(C)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 4/20 0.50
MMP14 P50281 1/20 0.50
ADAM17 P78536 1/20 0.50
GPR119 Q8TDV5 10/20 0.48
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
PBRM1 Q86U86 1/20 0.47
ADAMTS4 O75173 2/20 0.45
MAPT P10636 1/20 0.44
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ABCB1 P08183 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19691705 0.91 ADAMTS4 (0.56) ADAMTS5MMP14ADAM17GPR119SMARCA2
SCHEMBL19691704 0.91 ADAMTS4 (0.56) ADAMTS5MMP14ADAM17GPR119SMARCA2
SCHEMBL30005481 0.89 SMARCA2 (0.49) ADAMTS5ADAM17GPR119SMARCA2SMARCA4
SCHEMBL30005593 0.89 SMARCA2 (0.49) ADAMTS5ADAM17GPR119SMARCA2SMARCA4
SCHEMBL12208556 0.87 ADAMTS5 (0.52) ADAMTS5MMP14ADAM17GPR119SMARCA2
SCHEMBL27985660 0.86 LMNA (0.49) GPR119SMARCA2SMARCA4PBRM1MAPT
SCHEMBL21471227 0.83 SMARCA2 (0.52) ADAMTS5GPR119SMARCA2SMARCA4PBRM1
SCHEMBL652990 0.82 MEN1 (0.53) ADAMTS5GPR119SMARCA2SMARCA4PBRM1
SCHEMBL652991 0.82 MEN1 (0.53) ADAMTS5GPR119SMARCA2SMARCA4PBRM1
SCHEMBL17871458 0.82 GPR119 (0.48) ADAMTS5MMP14GPR119SMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10941117-B2 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV (BE) 2021-03-09 US disclosed
US-20200216397-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2020-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216397-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS ADAMTS1, ADAMTS5, ADAMTS7 ADAMTS5 2/4885MMP14 38/4885ADAM17 8/4885
US-10941117-B2 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis ADAMTS5, ADAMTS1, ADAMTS7 ADAMTS5 1/4885MMP14 37/4885ADAM17 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.